AP 003 - ArrePath
Alternative Names: AP-003 - ArrePathLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator ArrePath
- Class Antibacterials; Antibronchitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Bronchiectasis; Nontuberculous mycobacterium infections
Most Recent Events
- 18 Oct 2024 Early research in Bronchiectasis in USA (Inhalation) (ArrePath pipeline, August 2024)
- 18 Oct 2024 Early research in Bronchiectasis in USA (PO) (ArrePath pipeline, August 2024) (ArrePath pipeline, August 2024)
- 18 Oct 2024 Early research in Nontuberculous mycobacterium infections in USA (Inhalation) (ArrePath pipeline, August 2024)